SF Derm Society Annual Meeting Pearls
Filling in the Knowledge Gaps: A Summary of Dr. Amit Pandya and Dr. Iltefat Hamzavi's Panel on Vitiligo
Part II: Dr. Iltefat Hamzavi
Authors: Akachukwu Eze and Payton Smith
At the recent San Francisco Derm Society expert panel on vitiligo, Dr. Amit Pandya and Dr. Iltefat Hamzavi, leaders in vitiligo research and treatment, shared insights into the evolving landscape of vitiligo management. Their discussion touched on important clinical updates, treatment options, and the significant psychosocial impact the condition has on patients.
Dr. Hamzavi discussed the psychosocial challenges associated with vitiligo, noting that younger patients and those with darker skin are at higher risk for depression and low self-esteem. For these patients, a holistic approach that considers emotional well-being is critical.
Dr. Hamzavi described two types of vitiligo:
- Segmental vitiligo is often unilateral and typically affects one area of the body.
- Non-segmental vitiligo is more common and affects both sides of the body symmetrically.
Key Treatment Strategies: Vitiligo treatment generally follows three main goals:
- Reducing immune attack on the skin through corticosteroids, tacrolimus, pimecrolimus, JAK inhibitors, and phototherapy.
- Decreasing oxidative stress with antioxidants like Vitamin C/E and avoiding trauma to the skin.
- Increasing melanocyte migration from the hair follicle through treatments like phototherapy, afamelanotide, and skin or cellular grafts.
The importance of antioxidants in combating oxidative stress was emphasized, with ginkgo biloba mentioned as a notable option. Additionally, phototherapy remains a cornerstone of treatment, stimulating melanocyte activity and aiding repigmentation.
Recent Treatment Advances
The FDA approval of JAK inhibitors for vitiligo has been a significant development in the field. These inhibitors, such as tofacitinib, ritlecitinib, and ruxolitinib, have shown substantial promise, especially when combined with phototherapy, which can double the response rate (measured by the Vitiligo Area Scoring Index, or VASI).
In complex cases of segmental vitiligo that have not responded to medical treatments, autologous melanocyte transplantation has emerged as a surgical option. Techniques such as punch grafting, epidermal blister grafting, and cultured epidermal suspension grafting are showing success in promoting localized repigmentation.
Vitiligo in Challenging Areas
Vitiligo on hands and feet remains notoriously difficult to treat, particularly on the phalanges (finger bones). While the dorsum of the hand may respond better to treatment, camouflage makeup is often the best option for more resistant areas.
Depigmentation therapy using monobenzylhydroquinone 30% may be considered for patients with extensive vitiligo, although this is a psychologically challenging decision for many. This approach is usually reserved for those who desire complete depigmentation and have not responded to other therapies.
Psychosocial and Counseling Considerations
Dr. Pandya and Dr. Hamzavi underscored the need to address the psychosocial impact of vitiligo. Support groups and counseling are essential tools in helping patients cope with the emotional burden of the disease. Setting realistic expectations is crucial, especially for areas like the hands and feet that may not respond well to treatment.
In summary, Dr. Pandya and Dr. Hamzavi's insights highlight the importance of a comprehensive, patient-centered approach to vitiligo treatment. Advances in JAK inhibitors, new surgical techniques, and a better understanding of melanocyte biology are offering hope to patients.